Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance

Table 1 The clinical data of 134 pancreatic ductal adenocarcinoma patients

Items	Category	n (%)
Age (yr)	≤ 60	63 (47.0)
	> 60	71 (53.0)
Gender	Male	92 (68.7)
	Female	42 (31.3)
Location of tumor	Head	97 (72.4)
	Body/tail	37 (27.6)
Size of tumor (cm)1	≤ 2.0	17 (13.2)
	> 2.0	112 (86.8)
Histological grade	G1	3 (2.2)
	G2	116 (86.6)
	G3	15 (11.2)
Perineural invasion	Absent	25 (18.7)
	Present	109 (81.3)
pT1	T1	10 (7.6)
	T2	43 (32.8)
	T3	46 (35.1)
	T4	32 (24.4)
pN1	Absent	84 (65.1)
	Present	45 (34.9)
pTNM1	I	32 (24.8)
	II	30 (23.3)
	III	33 (25.6)
	IV	34 (26.4)

¹Some records are missing. pTNM: Pathological tumor-node-metastasis.

Table 2 Correlation of fibroblast activation protein expression with clinicopathological features of pancreatic ductal adenocarcinoma patients n (%)

Items	Category	n	FAP negative	FAP positive	P value
Age (yr)	≤ 60	63	19 (30.2)	44 (69.8)	0.000
	> 60	71	13 (18.3)	58 (81.7)
Gender	Male	92	22 (23.9)	70 (76.1)	0.990
	Female	42	10 (23.8)	32 (76.2)
Location of tumor	Head	97	27 (27.8)	70 (72.2)	0.082
	Body/tail	37	5 (13.5)	32 (86.5)
Size of tumor (cm)1	≤ 2.0	17	10 (58.8)	7 (41.2)	0.000
	> 2.0	112	21 (18.8)	91 (81.2)
Histological grade	G1	3	1 (33.3)	2 (66.7)	0.889
	G2	116	27 (23.3)	89 (76.7)
	G3	15	4 (26.7)	11 (73.3)
Fibrotic focus	Absent	13	7 (53.8)	6 (46.2)	0.003
	Present	47	7 (14.9)	40 (85.1)
Perineural invasion	Absent	25	11 (44.0)	14 (56.0)	0.009
	Present	109	21 (19.3)	88 (80.7)
pT1	T1	10	5 (50.0)	5 (50.0)	0.170
	T2	43	8 (18.6)	35 (81.4)
	T3	46	12 (26.1)	34 (73.9)
	T4	32	6 (18.8)	26 (81.2)
pN1	Absent	84	21 (25.0)	63 (75.0)	0.725
	Present	45	10 (22.2)	35 (77.8)
pTNM1	I	32	7 (21.9)	25 (78.1)	0.895
	II	30	8 (26.7)	22 (73.3)
	III	33	9 (27.3)	24 (72.7)
	IV	34	7 (20.6)	27 (79.4)

¹Some records are missing. pTNM: Pathological tumor-node-metastasis; FAP: Fibroblast activation protein.